A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease.

KidneyIntelX, a bioprognostic test for assessing risk of CKD progression, risk stratified individuals for kidney, heart failure, and death outcomes in the Canagliflozin Cardiovascular Assessment Study.Individuals scored as high risk seemed to derive more of benefit from treatment with canagliflozin versus placebo.These findings may serve to increase adoption of underutilized therapies for cardiorenal risk reduction in patients with diabetic kidney disease.
Competing Interests: S.G. Coca reports consultancy for Axon Therapies, Bayer, Boehringer Ingelheim, Nuwellis, Renalytix, Reprieve Cardiovascular, Takeda, Vifor, and 3ive; ownership interest in pulseData and Renalytix; research funding from ProKidney, Renalytix, Renal Research Institute, and XORTX; patents or royalties from Renalytix; being a scientific co-founder of Renalytix and having equity and royalties and being a consultant and member of the scientific advisory board; an advisory or leadership role with Renalytix and Reprieve Cardiovascular; and being an associate editor for Kidney360 and on the editorial boards of JASN, CJASN, and Kidney International. F. Fleming reports being the chief technology officer and co-founder of Renalytix; being an employee of Renalytix; ownership interest in Renalytix and Verici Dx; and having an advisory or leadership role with Renalytix. M. Hansen reports being an employee of Janssen Research & Development, and ownership interest in Johnson & Johnson. H.L. Heerspink reports being an employee of University Medical Center Groningen; ongoing consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, Chinook, Dimerix, Eli-Lilly, Gilead, GoldFinch, Janssen, Merck, NovoNordisk, and Travere Pharmaceuticals; research funding from AstraZeneca, Janssen research support (grant funding directed to employer), and NovoNordisk; honoraria from AstraZeneca (lecture fees); and participating in a speakers’ bureau for AstraZeneca. K. Mahaffey reports consultancy for Amgen, Applied Therapeutics, AstraZeneca, Bayer, CSL Behring, Elsevier, Fribrogen, Invo, Johnson & Johnson, Lexicon, Myokardia, Novartis, Novo Nordisk, Otsuka, Phasebio, Portola, Precordior, Quidel, Sanofi, and Theravance; research funding from the American Heart Assocation, Apple, Inc., Bayer, California Institute Regenerative Medicine, Eidos, Ferring, Gilead, Google (Verily), Idorsia, Johnson & Johnson, Luitpold, PAC-12, Precordior, and Sanifit; and honoraria from Amgen, Anthos, Applied Therapeutics, AstraZeneca, Bayer, CSL Behring, Elsevier, Inova, Intermountain Health, Johnson & Johnson, Medscae, Mount Sinai, Mundi Pharma, Myokardia, Novartis, Novo Nordisk, Otsuka, Portola, Sanofi, SmartMedics, and Theravance. G.N. Nadkarni reports consultancy for Daiichi Sankyo, GLG consulting, Qiming Capital, Reata, Renalytix, Siemens Healthineers, and Variant Bio; ownership interest in Data2Wisdom, LLC, Doximity, Nexus iConnect, Pensieve Health, Renalytix, and Verici; research funding from Renalytix; honoraria from Daiichi Sankyo; patents or royalties from Renalytix; an advisory or leadership role with Renalytix; participating in a speakers’ bureau with Daiichi Sankyo; and being a scientific co-founder of Renalytix and having equity and royalties and being a consultant and member of the scientific advisory board. B. Neal reports consultancy for Janssen Research & Development, LLC; research funding from the Australian National Health and Medical Research Council Principal Research Fellowship and Janssen; honoraria from Janssen Research & Development, LLC (paid to the institution); and serving on advisory boards and/or involvement in continuing medical education (CME) programs for Janssen, with any consultancy, honoraria, or travel support paid to his institution. D. Takale reports being an employee of Persistent. Y. Yavin reports being an employer of Janssen, and ownership interest in Bristol-Myers Squibb and Johnson & Johnson.
(Copyright © 2022 by the American Society of Nephrology.)